ReviewNature reviews. Gastroenterology & hepatology2012
The role of pharmacogenetics in nonmalignant gastrointestinal diseases.
Review in Nature reviews. Gastroenterology & hepatology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 14 citations in OpenAlex.
- Pharmacogenetics in IBS: update and impact of GWAS studies in drug targets and metabolism.Expert opinion on drug metabolism & toxicology · 2024Review
- Editorial: Exploration of genetic variation, drug response, and interactions between gastrointestinal disorders and other diseases.Frontiers in pharmacology · 2023Article
- Uncovering the pathophysiology of irritable bowel syndrome by exploring the gut-brain axis: a narrative review.Annals of translational medicine · 2021Review
- Role of cytochrome P450 polymorphisms and functions in development of ulcerative colitis.World journal of gastroenterology · 2019Review
- Personalized medicine in functional gastrointestinal disorders: Understanding pathogenesis to increase diagnostic and treatment efficacy.World journal of gastroenterology · 2019Review
- Personalized management in functional gastrointestinal disorders based on genomics: hope at last or just feigned praise?Therapeutic advances in gastroenterology · 2019Article
- Novel Diet, Drugs, and Gastric Interventions for Gastroparesis.Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2016Review
- Review article: biomarkers and personalised therapy in functional lower gastrointestinal disorders.Alimentary pharmacology & therapeutics · 2015Review
- Systems pharmacology identifies drug targets for Stargardt disease-associated retinal degeneration.The Journal of clinical investigation · 2013Article
- Irritable bowel syndrome: methods, mechanisms, and pathophysiology. Genetic epidemiology and pharmacogenetics in irritable bowel syndrome.American journal of physiology. Gastrointestinal and liver physiology · 2012Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
Genetic variation influences the absorption and efflux of drugs in the intestine, the metabolism of drugs in the liver and the effects of these drugs on their target proteins. Indeed, variations in genes whose products have a role in the pathophysiology of nonmalignant gastrointestinal diseases, such as IBD, have been shown to affect the response of patients to therapy. This Review provides an overview of pharmacogenetics in the management of nonmalignant gastrointestinal diseases on the basis of data from clinical trials. Genetic variants that have the greatest effect on the management of patients with IBD involve the metabolism of thiopurines. Variation in drug metabolism by cytochrome P450 enzymes also requires attention so as to avoid drug interactions in patients receiving tricyclic antidepressants and PPIs. Few genotyping tests are currently used in the clinical management of patients with nonmalignant gastrointestinal diseases, owing to a lack of data from clinical trials showing their effectiveness in predicting nonresponse or adverse outcomes. However, pharmacogenetics could have a beneficial role in enabling pharmacotherapy for nonmalignant gastrointestinal diseases to be targeted to the individual patient.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.